Molecular Partners AG (MOLN)
NASDAQ: MOLN
· Real-Time Price · USD
3.75
-0.15 (-3.85%)
At close: May 01, 2025, 3:49 PM
3.84
2.47%
Pre-market: May 02, 2025, 04:00 AM EDT
-3.85% (1D)
| Bid | 3.6 |
| Market Cap | 138.19M |
| Revenue (ttm) | 4.97M |
| Net Income (ttm) | -54.04M |
| EPS (ttm) | -1.94 |
| PE Ratio (ttm) | -1.93 |
| Forward PE | -1.68 |
| Analyst | n/a |
| Ask | 4.07 |
| Volume | 2,927 |
| Avg. Volume (20D) | 10,527 |
| Open | 3.63 |
| Previous Close | 3.90 |
| Day's Range | 3.63 - 3.86 |
| 52-Week Range | 3.36 - 12.70 |
| Beta | 0.61 |
About MOLN
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for th...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2021
Employees 158
Stock Exchange NASDAQ
Ticker Symbol MOLN
5 days ago
+2.94%
Molecular Partners shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+14.18%
Molecular Partners shares are trading higher after the company announced its radio-DARPin therapy candidate MP0712 was supported by in vivo data presented at the European Association of Nuclear Medicine Congress. The first-in-human start and initial clinical data are expected in 2025.
